It's not your father's generics industry anymore. The once dominant strategy of price competition has given way to consolidation, market dominance, proprietary development programs, and world-class patent litigators.
Contraceptive Conjugation
The intuitive appeal of Barr Laboratories' pooling-of-interest stock-swap acquisition of Duramed Pharmaceuticals is so clear that the temptation is to ask "What took so long?" The new Barr will offer a broad line of generic oral contraceptive products. Duramed also brings to Barr a formidable physician detailing force. Barr has built up a war chest by developing formulations and successfully challenging the validity of patents. Duramed, however, never recovered from its battle over the right to introduce a generic version of AHP's conjugated estrogens, Premarin. Now, with its legal, regulatory, and governmental affairs capabilities, Barr may re-open the Premarin case.
More from Business Strategy
• By
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
• By
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
• By
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
• By
Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
More from In Vivo
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.